William Blair analyst Ryan Daniels has reiterated their bullish stance on LFST stock, giving a Buy rating on February 23.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ryan Daniels has given his Buy rating due to a combination of factors, starting with LifeStance Health’s strong fourth-quarter performance that exceeded expectations on both revenue and adjusted EBITDA, supported by a new $100 million share repurchase authorization. He also highlights management’s upbeat 2026 guidance, which projects continued solid growth in sales, margins, and profitability, reinforcing confidence in the company’s forward trajectory.
Additionally, Daniels points to the success of recent productivity and strategic initiatives—such as enhanced clinician incentives, better utilization of existing capacity, and deployment of patient engagement tools—as key drivers of sustained volume growth and operational efficiency. He further emphasizes LifeStance’s differentiated in-network “clicks-and-mortar” model, combining mostly virtual care with in-person services in a growing behavioral health market, which he views as a competitive advantage that remains undervalued by the market and supports a favorable long-term investment thesis.
In another report released on February 23, Morgan Stanley also maintained a Buy rating on the stock with a $10.00 price target.